PDS Competitors

Stocks . Germany . 
Stock . PDS Biotechnology Corp
EU6 Stock  EUR 1.41  0.02  1.44%   
PDS Biotechnology Corp competes with Novo Nordisk, CSL, CSL, Mercedes-Benz Group, and Vertex Pharmaceuticals; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing PDS Biotechnology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of PDS Biotechnology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out PDS Biotechnology Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of PDS Biotechnology competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.071.416.44
Details
Intrinsic
Valuation
LowRealHigh
0.071.356.38
Details

PDS Biotechnology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between PDS Biotechnology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of PDS and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of PDS Biotechnology Corp does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CSJ
+ 0.96
CSJA
0QF
+ 0.8
CSJ
0QF
+ 0.78
CSJA
VX1
+ 0.71
NOVA
CSJA
+ 0.57
NOVA
CSJ
+ 0.57
NOVA
  
High negative correlations   
1FW1
- 0.5
NOVA
1FW1
- 0.49
VX1
22UA
- 0.45
VX1
1FW1
- 0.4
CSJA
22UA
- 0.38
NOVA
1FW1
- 0.37
CSJ

Risk-Adjusted Indicators

There is a big difference between PDS Stock performing well and PDS Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze PDS Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

PDS Biotechnology Competitive Analysis

The better you understand PDS Biotechnology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, PDS Biotechnology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across PDS Biotechnology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
EU6 NOVA CSJA CSJ MBG VX1 0QF 1FW1 22UA
 1.44 
 1.41 
PDS
 5.46 
 76.20 
Novo
 1.22 
 81.00 
CSL
 0.69 
 164.10 
CSL
 2.14 
 56.34 
Mercedes-Benz
 0.37 
 410.20 
Vertex
 6.28 
 35.39 
Moderna
 4.05 
 4.62 
WUXI
 2.06 
 109.60 
BioNTech
Market Volatility
(90 Days Market Risk)
Dangerous
Very steady
Very steady
Very steady
Very steady
Very steady
Not too volatile
Relatively risky
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
OK
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Quite High
Low
Low
Low
Low
Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Cautious Hold
Cautious Hold
Strong Sell
Strong Hold
Strong Sell
Hold
Sell
Current Ratio
19.22
0.96
2.93
2.93
2.38
3.74
1.24
3.16
2.67
Net Asset
67.2 M
241.26 B
N/A
28.35 B
259.83 B
18.15 B
25.86 B
N/A
15.83 B
Profit Margin
N/A
0.31
0.21
0.18
0.16
0.37
0.43
0.31
0.56
EBITDA
(21.43 M)
76.8 B
3.32 B
3.46 B
23.22 B
4.44 B
9.77 B
4.6 B
15.13 B
Current Valuation
189.69 M
282.15 B
N/A
91.69 B
129.51 B
67.44 B
69.44 B
N/A
29.68 B
Price To Book
5.63
27.5
N/A
6.69
0.85
6.23
4.46
N/A
2.31
Operating Margin
N/A
0.43
0.28
0.25
0.12
0.49
0.49
0.31
0.68
Five Year Return
N/A
2.26
N/A
1.48
N/A
N/A
N/A
N/A
N/A
Beta
1.91
0.33
0.18
0.19
1.31
0.46
1.64
1.11
0.2
Number Of Employees
22
54.39 K
30 K
30 K
172.43 K
4.8 K
3.9 K
10.59 K
4 K
Shares Outstanding
28.89 M
2.25 B
964.43 M
482.22 M
1.07 B
257.09 M
385 M
2.11 B
242.68 M
Cash Flow From Operations
(12.49 M)
78.89 B
1.6 B
2.63 B
24.55 B
4.13 B
4.98 B
1.88 B
889.7 M
Annual Yield
N/A
0.0124
0.0125
0.0114
0.072
N/A
N/A
N/A
0.0132
Total Debt
552.98 K
20.77 B
4.65 B
3.86 B
69.44 B
656.95 M
603 M
3.33 B
171.6 M
Return On Equity
-0.49
0.72
0.2
0.13
0.17
0.28
0.5
0.12
0.76
Z Score
N/A
8.4
12.0
13.8
0.6
64.2
49.8
5.4
N/A
Return On Asset
-0.25
0.22
0.0798
0.0631
0.0398
0.17
0.23
0.0551
0.43
Book Value Per Share
1.65
37.1
15.13
32.51
76.27
54.13
49.67
16.51
76.45
Total Asset
67.2 M
241.26 B
N/A
28.35 B
259.83 B
18.15 B
25.86 B
N/A
15.83 B
Debt To Equity
0.007
9.1
95.8
95.8
N/A
12.9
0.089
0.16
0.046
Target Price
19.71
116.88
N/A
N/A
110.9
258.59
N/A
N/A
334.89
Last Dividend Paid
N/A
12.4
2.22
2.25
5.0
N/A
N/A
N/A
N/A
Shares Owned By Institutions
23.77
8.34
0.07
35.53
35.03
96.26
68.06
0.007
18.41
Market Capitalization
206 M
303.37 B
95.48 B
89.54 B
78.76 B
70.82 B
50.28 B
32.39 B
30.49 B
Price To Earning
23.42
17.63
33.28
35.97
N/A
18.5
237.44
238.12
45.99
Price To Earnings To Growth
-0.29
2.0
N/A
N/A
53.14
0.42
N/A
N/A
0.0445
Price To Sales
N/A
1.68
N/A
8.43
0.46
8.51
3.48
N/A
2.19
Net Income
(16.92 M)
55.52 B
1.8 B
2.25 B
23.01 B
3.32 B
8.36 B
1.69 B
10.29 B
Earnings Per Share
-0.91
3.32
2.24
4.08
12.14
11.89
22.69
0.25
38.32
Shares Owned By Insiders
14.2
0.007
N/A
0.41
28.62
0.21
9.49
N/A
64.0
Revenue
N/A
176.95 B
10.56 B
10.49 B
133.89 B
8.93 B
19.26 B
13.09 B
18.98 B
Cash And Equivalents
74.75 M
1.64 B
668.7 M
668.7 M
3.42 M
3.95 B
7.99 B
8.48 B
914.9 M
Cash Per Share
2.63
0.67
0.74
1.48
2.32
15.37
19.8
4.15
3.75
Gross Profit
N/A
148.51 B
5.73 B
5.73 B
29.25 B
5.32 B
10.55 B
4.83 B
16.07 B
Day Typical Price
1.41
77.4
81.17
164.1
56.0
410.2
35.15
4.62
109.53
Accumulation Distribution
N/A
0.05
0.0061
N/A
202.08
N/A
133.74
N/A
27.95
Market Facilitation Index
N/A
4.0
0.5
N/A
4.0E-4
N/A
1.0E-4
N/A
0.0029
Daily Balance Of Power
9.2 T
(1.10)
(2.00)
(9,223,372,036,855)
0.5488
9.2 T
2.824324
9.2 T
(0.77)
Period Momentum Indicator
0.02
(4.40)
(1.00)
(1.14)
1.18
1.5
2.09
0.18
(2.30)
Rate Of Daily Change
1.01
0.95
0.99
0.99
1.02
1.0
1.06
1.04
0.98
Day Median Price
1.41
78.0
81.25
164.1
55.83
410.2
35.03
4.62
109.5
Price Action Indicator
0.01
(4.00)
(0.75)
(0.57)
1.11
0.75
1.41
0.09
(1.05)
Coefficient Of Variation
(461.91)
(642.29)
(842.81)
(766.62)
(5,401)
(2,683)
(894.81)
1240.92
6931.97
Mean Deviation
3.66
1.89
1.06
0.955
1.11
1.38
3.29
3.0
2.29
Jensen Alpha
(1.10)
(0.50)
(0.18)
(0.17)
(0.04)
(0.12)
(0.53)
0.3049
0.0236
Total Risk Alpha
(1.18)
(0.58)
(0.21)
(0.19)
(0.08)
(0.16)
(0.62)
0.2244
(0.04)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0764
0.0048
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
15.6
9.86
Standard Deviation
4.88
3.17
1.4
1.18
1.55
2.46
4.54
4.11
3.11
Kurtosis
1.4
18.43
0.8761
(0.65)
2.86
14.4
1.88
1.95
0.357
Potential Upside
5.79
3.26
2.41
1.92
2.52
2.48
6.28
6.56
5.82
Treynor Ratio
(0.69)
4.23
(0.75)
(0.97)
1.67
(0.13)
(0.57)
0.3864
0.0613
Maximum Drawdown
22.7
22.78
6.98
4.44
7.42
20.51
28.12
23.89
14.85
Variance
23.83
10.08
1.97
1.39
2.4
6.04
20.57
16.9
9.65
Market Risk Adjusted Performance
(0.68)
4.24
(0.74)
(0.96)
1.68
(0.12)
(0.56)
0.3964
0.0713
Risk Adjusted Performance
(0.17)
(0.12)
(0.1)
(0.11)
(0.01)
(0.02)
(0.09)
0.0753
0.0194
Skewness
(0.24)
(3.09)
0.3853
0.1938
(0.71)
(1.94)
(0.33)
0.5514
(0.03)
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3.47
3.04
Information Ratio
(0.22)
(0.17)
(0.14)
(0.16)
(0.04)
(0.05)
(0.12)
0.0734
0.0049
Value At Risk
(9.27)
(4.20)
(2.34)
(2.10)
(2.06)
(2.69)
(8.86)
(5.35)
(6.01)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(3.52)
(2.41)
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3.95
3.14
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
12.05
9.22

PDS Biotechnology Competition Performance Charts

Five steps to successful analysis of PDS Biotechnology Competition

PDS Biotechnology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by PDS Biotechnology Corp in relation to its competition. PDS Biotechnology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of PDS Biotechnology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact PDS Biotechnology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to PDS Biotechnology Corp, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your PDS Biotechnology position

In addition to having PDS Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Candy and Soda Thematic Idea Now

Candy and Soda
Candy and Soda Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Candy and Soda theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Candy and Soda Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in PDS Stock

When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:
How To Invest In PDS
Details
Is PDS Stock a good investment?
Details
What is PDS Biotechnology's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out PDS Biotechnology Correlation with its peers.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY